Coronavirus Disease 2019 (COVID-19): A literature review

Authors

  • Gusti Ayu Putu Laksmi Puspa Sari Magister Farmasi Fakultas Farmasi Universitas Surabaya Author

Keywords:

COVID-19, SARS-CoV-2, Pandemi, Bencana Nasional, Review

Abstract

Kasus pertama COVID-19 dilaporkan pada Desember 2019 ketika sekelompok pasien dirawat di rumah sakit di Wuhan, ibukota provinsi Hubei di Cina, yang disebabkan oleh Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Awalnya, berjangkitnya SARS CoV-2 hanya terbatas di provinsi Hubei, tetapi menyebar dengan cepat ke banyak negara lain, dan Organisasi Kesehatan Dunia secara resmi mendeklarasikan pandemi global pada 11 Maret 2020. Secara umum, coronavirus menyebabkan penyakit sistem pernapasan, pencernaan, dan sistem saraf pusat yang meluas pada manusia dan hewan lain, mengancam kesehatan manusia dan menyebabkan kerugian ekonomi. Masih banyak kontroversi seputar penyakit ini, termasuk tata laksana hingga pencegahan. Oleh karena itu, saya melakukan telaah terhadap studi-studi terkait COVID-19. Dalam ulasan literatur ini, penyebab, patogenesis dan respon imun, epidemiologi, diagnosis, perawatan dan manajemen strategi penyakit, kontrol dan pencegahan semuanya ditinjau.

References

[1] Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. JAMA Netw Open 2020;3:e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857.

[2] Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health 2020;13:667–73. https://doi.org/10.1016/j.jiph.2020.03.019.

[3] Kakodkar P, Kaka N, Baig M. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus 2020;2019. https://doi.org/10.7759/cureus.7560.

[4] B. S, K. S, K. W, W. P. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pacific J Allergy Immunol 2020. https://doi.org/10.12932/AP-200220-0773 LK - http://huji-primo.hosted.exlibrisgroup.com/openurl/972HUJI/972HUJI_SP?sid=EMBASE&sid=EMBASE&issn=0125877X&id=doi:10.12932%2FAP-200220-0773&atitle=Perspectives+on+monoclonal+antibody+therapy+as+potential+therapeutic+intervention+for+Coronavirus+disease-19+%28COVID-19%29&stitle=Asian+Pac.+J.+Allergy+Immunol.&title=Asian+Pacific+journal+of+allergy+and+immunology&volume=&issue=&spage=&epage=&aulast=Shanmugaraj&aufirst=Balamurugan&auinit=B.&aufull=Shanmugaraj+B.&coden=&i.

[5] Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of covid-19. Viruses 2020;12:1–17. https://doi.org/10.3390/v12040372.

[6] Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review. Infect Dis Poverty 2020;9. https://doi.org/10.1186/s40249-020-00646-x.

[7] Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: A commentary. BMC Infect Dis 2019;19:1–9. https://doi.org/10.1186/s12879-019-3707-y.

[8] Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J 2020;55:9–11. https://doi.org/10.1183/13993003.00607-2020.

[9] Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res 2020;7:1–10. https://doi.org/10.1186/s40779-020-00240-0.

[10] Kementrian Kesehatan. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (covid-19) 2020;3:1–116.

[11] Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433. https://doi.org/10.1016/j.jaut.2020.102433.

[12] Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020;87:281–6. https://doi.org/10.1007/s12098-020-03263-6.

[13] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA - J Am Med Assoc 2020;323:1824–36. https://doi.org/10.1001/jama.2020.6019.

[14] Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19. Clin Pharmacol Ther 2020;0:1–11. https://doi.org/10.1002/cpt.1857.

[15] Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm 2012;2012. https://doi.org/10.1155/2012/649570.

[16] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020;382:1787–99. https://doi.org/10.1056/NEJMoa2001282.

[17] Sodhi M, Etminan M. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19. Pharmacotherapy 2020;40:487–8. https://doi.org/10.1002/phar.2395.

[18] Jankun J. COVID-19 pandemic?; transmembrane protease serine 2 ( TMPRSS2 ) inhibitors as potential therapeutics for SARS-CoV-2 coronavirus . 2020;2:19–23.

[19] Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.

Downloads

Published

2024-11-14

Issue

Vol. 2 No. 4 (2020): J. Sains Kes.

Section

Review

How to Cite

[1]
G. A. P. L. P. Sari, “Coronavirus Disease 2019 (COVID-19): A literature review”, J. Sains. Kes, vol. 2, no. 4, pp. 548–557, Nov. 2024, Accessed: Nov. 04, 2025. [Online]. Available: http://jsk.ff.unmul.ac.id/index.php/JSK/article/view/290

Similar Articles

21-30 of 227

You may also start an advanced similarity search for this article.